Marinus Pharmaceuticals


Marinus Pharmaceuticals is dedicated to developing innovative therapies for neurological disorders, with a focus on epilepsy and other serious conditions. Their mission is to improve the lives of patients through scientific research and clinical development.

Industries

biopharma
biotechnology
health-diagnostics
pharmaceutical
therapeutics

Nr. of Employees

medium (51-250)

Marinus Pharmaceuticals

Branford, Connecticut, United States, North America


Patents

Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders

US-12268696-B2

View Details

Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders

US-12115169-B2

View Details

Products

Investigational neuroactive therapeutic for epilepsy-related disorders

An investigational neuroactive therapeutic candidate under clinical development for treatment of seizures and epilepsy-related rare disorders (pipeline references to multiple indications).


Services

Medical-scientific engagement, clinical information dissemination, and poster/publication support for clinical stakeholders.

Administration of pre-approval/patient access programs for investigational therapies.

Support mechanisms for external investigators conducting studies using investigational agents.

Telehealth services and remote patient engagement to support treatment access and monitoring.

Expertise Areas

  • Clinical trial management (neurology)
  • Rare disease and epilepsy therapeutics development
  • Managed access and compassionate use programs
  • Medical affairs and scientific communications
  • Show More (4)

Key Technologies

  • Neuroactive therapeutic development (small-molecule/investigational therapeutics)
  • Clinical development platform for neurology indications
  • Telehealth delivery for patient support
  • Managed access program processes
  • Show More (2)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.